A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the tolerability, safety and efficacy of flexibly dosed paliperidone extended release (ER) among patients with schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Pharmaceutica
• Treatments: Paliperidone Palmitate

Criteria

Inclusion Criteria:

• Patients diagnosed with schizophrenia

• Patient with Positive and Negative Syndrome Scale (PANSS) score of 80 to 120 at screening

• Patients who have not taken any antipsychotics in the past, and those were newly diagnosed with schizophrenia who have not taken any antipsychotics for at least one month prior to screening

• Patient healthy on the basis of a physical examination, laboratory examination, and vital signs

• Women must have a negative pregnancy test, and agree to practice an effective method of birth control before entry and throughout the study

Exclusion Criteria:

• Serious unstable medical condition, including known clinically relevant laboratory abnormalities

• Judged to be at high risk for adverse events, violence or self-harm

• Inability to swallow the study medication whole with the aid of water (patients may not chew, divide, dissolve, or crush the study medication)

• Biochemistry results that are out of the laboratory's normal reference range and are deemed to be clinically significant by the investigator

• Patients with a current use or known history (over the past 6 months) of substance dependence

• Positive urine drug examination